RxSight appoints former Axonics CEO Raymond Cohen to board of directors

RxSight, Inc.

Raymond W. Cohen, former CEO of Axonics (sold to BSX for $3.7B), appointed to RxSight board as Class I director effective July 31, 2025.
Cohen also led SoniVie sale to Boston Scientific for $600M; has over 40 years medtech experience.
Will serve until 2028 annual meeting; receives standard non-employee director compensation including $277,500 initial RSU grant.
Press release issued August 4, 2025; no other changes to board or management.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.